Cancer-induced mutations and alterations of signaling pathways activate PI3K-Akt, which promotes transcriptional induction of glucose transporters [e.g., glucose transporter 1 (GLUT1)], activation of glycolytic enzymes (e.g., HK2, PFKFB3), and parallel activation of mTOR. Here, HK2 is linked to cancer.